Previously, Scott served as Executive Chairman at Cairn and has held prominent roles such as President and COO of Ironshore ...

Ultimately, the healthiest canned food for your cat is nutritionally complete and balanced for their life stage and any ... Chewy Best for older cats: Hill's Science Diet Adult 7+ Savory Chicken ...

Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

In a report released today, Falko Friedrichs from Deutsche Bank maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics , according to people familiar with the matter.

and Gilead Sciences. According to TipRanks, Bansal has an average return of 5.5% and a 53.68% success rate on recommended stocks. In addition to Wells Fargo, Merck & Company also received a Hold ...

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by ...

KGaA (MRK:GR) (OTC: MKGAF) stock from Overweight to Equalweight and reduced its price target from EUR190.00 to EUR160.00. The downgrade reflects a shift in the investment firm's perspective on the ...

(Reuters) -Merck said on Tuesday it would not ship its HPV vaccine Gardasil in China until at least the middle of this year due to weak discretionary spending, a move that dented its full-year ...

Merck reported Q4 sales of $15.62 billion, up 7% YoY, exceeding the $15.49 billion estimate. Goldman Sachs raises Merck's price target to $135, citing growth potential. NOW OPEN: 200 Charter ...

For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.